About Perceptive Advisors
Perceptive Advisors is a venture capital firm founded in 1999. It is primarily based out of New York City, United States. As of Sep 2026, Perceptive Advisors is an active investor, having invested in 214 companies, with 8 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Post IPO round of Lisata Overall, Perceptive Advisors portfolio has seen 5 unicorns, 95 IPOs and 56 acquisitions including key companies like BridgeBio, Omada and Biodesix. A lot of funds co-invest with Perceptive Advisors, with names like RA Capital Management sharing a substantial percentage of its portfolio. Perceptive Advisors has team of 25 people including 10 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Post IPO & 9 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Perceptive Advisors' List of Top Investments
Perceptive Advisors has a portfolio of 214 companies, including 5 unicorns. Their most notable investments are in IsoPlexis and Counsyl.Their portfolio spans across United States, United Kingdom, Canada and 8 more locations. They have invested in Life Sciences, High Tech, HealthTech and 12 other sectors, across stages such as Series B, Post IPO and 9 more. Here is the list of top investments by Perceptive Advisors:
1. BridgeBio
Developer of therapeutics for the treatment of genetic diseases. It utilizes a mapping of various genetic disease landscapes to identify opportunities for therapeutic intervention. The company's drug candidates include PTCH1-inhibitor for Gorlin syndrome and S1P-lyase inhibitor for Darier disease and Hailey-Hailey disease and others.
Key facts about BridgeBio
- Founded Year: 2015
- Location: Palo Alto (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $434M
- Employee Count: 1,064 as on Sep 30, 2026
- Investors: Perceptive Advisors, Athyrium Capital Management and 21 Others
- Latest Funding Round: Post IPO, Apr 30, 2024, $*****
- Highlight: Public
2. Omada
Provider of virtual care programs to manage chronic diseases. The company provides access to personal health coaches and specialists for virtual programs to deliver personalized interventions for prediabetes, diabetes, hypertension, and musculoskeletal issues.
Key facts about Omada
- Founded Year: 2011
- Location: San Francisco (United States)
- Stage: Public
- Total Funding till date: $450M
- Employee Count: 995 as on Aug 31, 2026
- Investors: Carriage House Rock, Perceptive Advisors and 45 Others
- Latest Funding Round: Series E, Feb 23, 2022, $*****
- Highlight: Public
3. Biodesix
Developer of diagnostics assays for the detection of cancer. The company offers invitro-diagnostic tests including Nodify Lung testing consisting of two blood-based proteomic tests, to identify the risk of malignancy of a lung nodule, and GeneStrat NGS a broad tumor mutation testing.
Key facts about Biodesix
- Founded Year: 2005
- Location: Boulder (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $200M
- Employee Count: 363 as on Aug 31, 2026
- Investors: Lincoln Park Capital, Perceptive Advisors and 1 Other
- Latest Funding Round: Post IPO, Nov 23, 2022, $*****
- Highlight: Public
4. CareDx
Developer of medical solutions for transplant patients. It has developed precision medicine solutions that offer products, testing services, and digital healthcare solutions along with the pre-and post-transplant patient journey. It provides AlloSure products for a kidney transplant. It is a non-invasive donor-derived cell-free DNA test for identifying kidney injury. It can determine active rejection, enabling better management of your kidney transplant patients. Other products include heart transplants, lab products, remotrac, and others.
Key facts about CareDx
- Founded Year: 1998
- Location: Brisbane (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $138M
- Employee Count: 856 as on Sep 30, 2026
- Investors: Intel, Integral Capital Partners and 25 Others
- Latest Funding Round: Conventional Debt, Mar 01, 2018, $*****
- Highlight: Public
Developer of oncology-focused precision medicine using molecular diagnostics. The lead candidate IDE196 is a protein kinase C an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. Others include PARG, WRN, poltheta, Darovasertib, and others.
Key facts about Ideaya Biosciences
- Founded Year: 2015
- Location: San Francisco (United States)
- Stage: Public
- Total Funding till date: $157M
- Employee Count: 283 as on Sep 30, 2026
- Investors: BVF Partners, Boxer Capital and 15 Others
- Latest Funding Round: Post IPO, Aug 04, 2020, $*****
- Highlight: Public
Perceptive Advisors' Year-on-Year Investment Trends
Perceptive Advisors has invested in 215 companies over the last 19 years, with an average of 16 new investments annually in the last 10 years. In 2025, it made 5 investments, while as of Sep 2026, it has made 10 investments in this year. Its most recent first time investment was in Lisata and most recent follow-on round was in Alto Neuroscience.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 7 | 3 | 10 |
2025 | 3 | 2 | 5 |
2024 | 15 | 7 | 22 |
2023 | 5 | 4 | 9 |
2022 | 7 | 8 | 15 |
2021 | 29 | 7 | 36 |
2020 | 29 | 13 | 42 |
2019 | 26 | 6 | 32 |
2018 | 22 | 4 | 26 |
2017 | 12 | 2 | 14 |
Perceptive Advisors' Investments by Stage
Perceptive Advisors has made 56 investments in Series B stage with an average round size of $83.3M, 40 investments in Post IPO stage with an average round size of $111M and 24 investments in Series A stage with an average round size of $72M.Stage of entry | No. of Investments |
|---|---|
Series B | 56 |
Post IPO | 40 |
Series A | 24 |
Series C | 24 |
Conventional Debt | 16 |
Others | 29 |
Note: We have considered here, only first round of investments
Perceptive Advisors' Investments by Sector
Perceptive Advisors has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Enterprise Applications and Sustainability Tech. Notably, it has invested in 189 Tech companies, 181 Enterprise (B2B) companies, 26 Software companies and at least 23 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 169 |
High Tech | 36 |
HealthTech | 22 |
Enterprise Applications | 14 |
Sustainability Tech | 13 |
Others | 30 |
Note: We have considered here, only first round of investments
Perceptive Advisors' Investments by Geography
Perceptive Advisors has made most investments in United States (160), followed by United Kingdom where it has made 8 investments.Country | No. of Investments |
|---|---|
United States | 160 |
United Kingdom | 8 |
Canada | 6 |
France | 4 |
China | 3 |
Others | 8 |
Note: We have considered here, only first round of investments
Perceptive Advisors' recent investments
Perceptive Advisors has made 10 investments in 2026 so far. Lisata and Vaderis are the latest among them.Here are the most recent investments by Perceptive Advisors:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 18, 2026 | United States | Post IPO | 9237 | [+11] | |
Aug 11, 2026 | Switzerland | Series B | 5097 | [+6] | |
Aug 10, 2026 | United States | Series B | 8529 | [+8] | |
May 20, 2026 | United States | Series D | 6841 | [+12] | |
May 18, 2026 | United States | Post IPO | 6745 |
Unicorns in Perceptive Advisors' Portfolio
Perceptive Advisors has 5 unicorns in its portfolio - Talkiatry, Kindbody, Freenome Health and others. The most recent unicorn in their portfolio is Talkiatry. It became a unicorn in 2026, 1 years after Perceptive Advisors first invested in it.Here is a list of unicorns in Perceptive Advisors' portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
64 | Provider of virtual, insurance-covered psychiatry services. It offers online assessments, connects patients with psychiatrists, and develops treatment plans including medication and therapy. The practice specializes in various mental health conditions such as anxiety, depression, bipolar disorder, ADHD, OCD, and PTSD, also providing care for children and adolescents and during pregnancy and postpartum. Psychiatrists conduct thorough evaluations and diagnoses, creating personalized treatment plans. The service aims to improve access to mental healthcare through virtual visits and insurance coverage. | 2020 | New York City | Series D | ypv{xnl | ||
53 | Provider of fertility services for women | 2018 | New York City | Series D | nhzstfu | ||
67 | Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | - | Series E | znlkvyk | ||
71 | Provider of home care and senior care services | 2014 | Omaha | Series E | tudxazc | ||
65 | Manufacturer of focused ultrasound platforms for treating neurological movement disorders | 1999 | Tirat Carmel | Series G | qwwgfmi |
IPOs and Publicly Listed companies in Perceptive Advisors' Portfolio
95 of Perceptive Advisors' portfolio companies have become public. Scribe Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jul 2026 at marketcap of $243M and Kardigan got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $1.43B.Here are Perceptive Advisors' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 24, 2026 | Mar 17, 2021 | Series B | 9981 | |
Jun 18, 2026 | Jan 13, 2025 | Series A | 3447 | |
Apr 30, 2026 | Sep 27, 2023 | Series C | 5494 | |
Aug 15, 2025 | Jul 26, 2016 | Series C | 6248 | |
Jun 18, 2025 | Apr 07, 2025 | Series D | 5167 |
Acquired companies in Perceptive Advisors' Portfolio
56 companies from Perceptive Advisors' portfolio have been acquired. The most recent acquisition was Vital Connect in Aug 2026 by iRhythm Tech for $*****.Here are Perceptive Advisors' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 06, 2026 | Jun 13, 2016 | Conventional Debt | 4687 | |
Jul 06, 2026 | Feb 21, 2018 | Series B | 2926 | |
Mar 06, 2026 | Feb 01, 2021 | Series B | 6305 | |
Jan 21, 2026 | Sep 18, 2026 | Post IPO | 2309 | |
Jan 20, 2026 | Dec 23, 2024 | Post IPO | 1084 |
Team profile of Perceptive Advisors
Perceptive Advisors has a team of 25 members including 10 Partners and 6 Principals located in United States. Perceptive Advisors' team sits on the board of 1 company.Here is a list of top team members in Perceptive Advisors:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | New York City | - | - | |
Partner | New York City | - | - | |
Partner | New York City | - | - | |
Partner | New York City | - | - | |
Partner | New York City | - | - | |
Partner | New York City | - | - | |
Partner | Mobile | - | - | |
Partner | Boston | - | ||
Partner | - | - | - | |
Partner | - | - | - | |
Principal | New York City | - | - |
Co-investors of Perceptive Advisors
Over the past 19 years, 1205 investors have co-invested in Perceptive Advisors's portfolio companies. This includes funds and angels.
- Invested before Perceptive Advisors: HHS, Orbimed and 598 others have invested in rounds before Perceptive Advisors. There are 26 companies where HHS has invested before Perceptive Advisors and 15 companies where Orbimed has invested before Perceptive Advisors.
- Top Co-investors of Perceptive Advisors: 351 investors entered a company along with Perceptive Advisors. These include investors like RA Capital Management (33 companies).
- Invested after Perceptive Advisors: A total of 254 investors have invested in Perceptive Advisors's portfolio after their investments. Top Investors include Fidelity Investments (8 companies), EcoR1 (7 companies) and Citadel (6 companies).
Recent News related to Perceptive Advisors
•
Superluminal Medicines Secures $60 Million for Rare Obesity Therapy DevelopmentPharmaceutical Business Review•Sep 04, 2026•Deep Track Capital, Insight Partners, Nvidia, Cooley and 9 others
•
Trinity Biotech plc (TRIB) Stock: Jumps as Perceptive Advisors Backs $7M Investment and Nasdaq Compliance RestoredBitcoin Ethereum News•Aug 15, 2026•Trinity Biotech, Perceptive Advisors
•
Zymeworks Inc. $ZYME Shares Purchased by Perceptive Advisors LLCTranscript Daily•Aug 02, 2026•Perceptive Advisors, Zymeworks
•
Freenome Completes Business Combination and Becomes Publicly Traded CompanyGlobeNewswire•Jul 21, 2026•Perceptive Advisors, Freenome Health
•
The market value has soared by more than 1,300%. How can a pharmaceutical company that failed in phase III clinical trials "escape from death"?TMTpost•Jun 05, 2026•Soleus Capital, Perceptive Advisors, Adlai Nortye, MPM BioImpact and 1 other
•
Adlai Nortye Announces $150.0 Million Private PlacementGlobeNewswire•Apr 16, 2026•Perceptive Advisors, Soleus Capital, Adlai Nortye
•
Imperative Care Raises $100M in FundingFinSMEs•Mar 18, 2026•Patient Square Capital, Imperative Care, Bain Capital Life Sciences, Perceptive Advisors and 7 others
•
Solid Biosciences Announces Oversubscribed $240 Million Private PlacementBenzinga•Mar 06, 2026•Solid Biosciences, Bain Capital Life Sciences, Perceptive Advisors
•
Medincell Announces Private PlacementFortuneo•Mar 05, 2026•MedinCell, Affinity Asset Advisors, Perceptive Advisors, Kurma Partners and 1 other
•
Talkiatry Announces $210M Series D RoundMassinvestor•Feb 13, 2026•Talkiatry, Perceptive Advisors, Andreessen Horowitz, Left Lane Capital and 3 others
